KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Return on Sales (2016 - 2025)

Biomarin Pharmaceutical's Return on Sales history spans 17 years, with the latest figure at 0.05% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales fell 22.0% year-over-year to 0.05%, compared with a TTM value of 0.11% through Dec 2025, down 4.0%, and an annual FY2025 reading of 0.11%, down 4.0% over the prior year.
  • Return on Sales for Q4 2025 was 0.05% at Biomarin Pharmaceutical, down from 0.04% in the prior quarter.
  • The five-year high for Return on Sales was 0.29% in Q2 2025, with the low at 0.13% in Q4 2021.
  • Average Return on Sales over 5 years is 0.07%, with a median of 0.06% recorded in 2022.
  • Year-over-year, Return on Sales tumbled -174bps in 2021 and then increased 20bps in 2022.
  • Tracing BMRN's Return on Sales over 5 years: stood at 0.13% in 2021, then skyrocketed by 100bps to 0.0% in 2022, then surged by 6907bps to 0.03% in 2023, then surged by 430bps to 0.17% in 2024, then tumbled by -132bps to 0.05% in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Return on Sales are 0.05% (Q4 2025), 0.04% (Q3 2025), and 0.29% (Q2 2025).